ZyVersa Therapeutics Unveils Positive Data Showing Potential to Protect Pancreatic Cells and Slow Progression from Obesity to Type 2 Diabetes, Shares Rise 41%

ZyVersa Therapeutics (NASDAQ: ZVSA) announced positive data highlighting the potential of its inflammasome inhibitor, IC 100, in preserving pancreatic islet beta cells and reducing inflammation-related damage that contributes to insulin resistance and type 2 diabetes. Published research showed that inhibiting the inflammasome NLRP3 pathway in an obesity model helped protect and restore beta cell function, improving overall metabolic health.

Stephen C. Glover, ZyVersa’s CEO and President said, “We are excited about the potential of IC 100 to effectively control the inflammation of obesity. Unlike the NLRP3 inhibitors in development, IC 100 targets ASC to inhibit multiple inflammasomes, including NLRP3 and AIM2, which are activated in obesity. More importantly, IC 100 uniquely disrupts the function of ASC specks to attenuate the chronic, systemic inflammation leading to obesity comorbidities. We look forward to progressing IC 100’s obesity development program into phase 1 around mid-2025.”

This supports ZyVersa’s development of IC 100 as a complementary treatment to incretin therapies for managing obesity and related conditions. Following this news, ZyVersa’s stock rose by 41%.